Skip to content
MarketScale
‹ Back to IndustriesSciences

Leaders Driving Change at SXSW: Part One

Learning about and experimenting with new products is what makes attending an event like SXSW an enjoyable and worthwhile endeavor. Hearing specific stories of how these developments have already saved lives and changed the world elevates the SXSW experience from one of intrigue to captivation. MarketScale conversed with 10 SXSW speakers about their new…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Healthcare · Heather Watson PodcastNigel Mcalpine PodcastSxsw PodcastTatyana Kanzaveli Podcast
Share

Key takeaways

01

Learning about and experimenting with new products is what makes attending an event like SXSW an enjoyable and worthwhile endeavor.

02

Hearing specific stories of how these developments have already saved lives and changed the world elevates the SXSW experience from one of intrigue to captivation.

03

MarketScale conversed with 10 SXSW speakers about their new…

Learning about and experimenting with new products is what makes attending an event like SXSW an enjoyable and worthwhile endeavor. Hearing specific stories of how these developments have already saved lives and changed the world elevates the SXSW experience from one of intrigue to captivation.

MarketScale conversed with 10 SXSW speakers about their new products and experiences from the past year. From marketing to lifesaving surgery, this year’s conference has truly brought together some of the world’s foremost innovators in a wide gamut of industries.

Tim Brown and Nigel McAlpine

Augmented reality and 3D printing are often viewed as innovations that can enhance fun. Dr. Tim Brown Consultant Transplant Surgeon at Belfast City Hospital in Northern Ireland and Nigel McAlpine, Immersive Technology lead at Digital Catapult proved these developments can be much more impactful. Lifesaving, in fact.

Hear the story of how these two were involved in saving a young woman’s life by using 3D printing and augmented reality to rid a kidney of a tumor so that it could be transplanted into her body before it was too late.

“She didn’t have long to go, and it was very unlikely that she was going to get a transplant to save her life,” Dr. Brown said of the initial prognosis.

The pair brought to SXSW 2019 an exact replica of the donor’s kidney, which was 3D-printed by Axial3D.

“They’ve done it specially to our specifications, we’ve asked for a clear kidney and they’ve marked the tumor for us very clearly and helpfully to show us what we need chop out to make this kidney transplantable,” Dr. Brown continued.

Dr. Brown and McAlpine will be part of a panel discussing the procedure on Tuesday, March 12 at 12:30 p.m. CST.

Tatyana Kanzaveli

Tatyana Kazaveli, CEO of Open Health Network is also involved in cutting edge technology in the healthcare industry.

She helped explain how blockchain has made tangible impacts in the field and how the public can learn more about its results and move away from unsubstantiated hype.

“In healthcare I see baby steps. Mostly I see initiatives by pharma companies but there are career use cases for providers, insurance companies and pharma and researchers. But they’re still baby steps and I’m glad we’ve developed something that has actually deployed, and it does give a value as is,” she said of Open Healthcare and the state of blockchain in the medical world.

She will be elaborating on this topic on Tuesday, March 12 at 11 a.m. but gave MarketScale the lay of the land for blockchain today.

Heather Watson

Businesses must know their customer to be successful, but in this digital age, knowing how to find these customers might be more important. With Gen Z beginning to research products and order through social media and ordering products on cell phones and tablets, brands must react.

Heather Watson, behavioral designer for the Center for Generational Kinetics, LLC, has been researching how Gen Z will change the global economy, and what the next wave of workers expects from the job market, working environment and more.

“Their life digitally is as important as their physical life,” Watson said of Gen Z.

She explained how parenting, global trends and technology have transformed business and retail, and how the evolution of social media from a platform to a legitimate retail market will continue.

“One third of teenagers, or Gen Z, are on their phones after midnight every night. That is a powerful habit. They are on their phones 6-7 hours a day,” Watson said.

These habits are not going away soon, according to Watson, and marketing and advertising must learn to reach their customers in new ways.

About the author

H
Healthcare

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

H
Healthcare

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512